GALLBLADDER CANCER
Clinical trials for GALLBLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new GALLBLADDER CANCER trials appear
Sign up with your email to follow new studies for GALLBLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise in Hard-to-Treat biliary cancers
Disease control OngoingThis phase II trial tests whether adding the targeted drug selumetinib to standard chemotherapy (cisplatin and gemcitabine) works better than chemotherapy alone for advanced biliary tract or gallbladder cancer. The study enrolls 57 adults who have not had prior treatment. Researc…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThis study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New chemo mist targets abdominal cancer with fewer side effects
Disease control TerminatedThis early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune cells take on rare bile duct cancer in early trial
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cocktail of drugs shows promise for bile duct cancer
Disease control OngoingThis study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail targets HER2-Positive bile duct cancer in small trial
Disease control OngoingThis phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination …
Matched conditions: GALLBLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvat…
Matched conditions: GALLBLADDER CANCER
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New PET scan aims to spot hidden cancers with precision
Diagnosis OngoingThis study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…
Matched conditions: GALLBLADDER CANCER
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC